WO1992011367A2 - Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof - Google Patents
Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof Download PDFInfo
- Publication number
- WO1992011367A2 WO1992011367A2 PCT/US1991/009810 US9109810W WO9211367A2 WO 1992011367 A2 WO1992011367 A2 WO 1992011367A2 US 9109810 W US9109810 W US 9109810W WO 9211367 A2 WO9211367 A2 WO 9211367A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- receptor
- adhesin protein
- adhesin
- microorganism
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 65
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract description 6
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims abstract description 101
- 230000027455 binding Effects 0.000 claims abstract description 42
- 150000002632 lipids Chemical class 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- 230000000813 microbial effect Effects 0.000 claims abstract description 19
- 239000003085 diluting agent Substances 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 9
- 229960005486 vaccine Drugs 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- 210000004027 cell Anatomy 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 65
- 239000000284 extract Substances 0.000 claims description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 26
- 150000003904 phospholipids Chemical class 0.000 claims description 26
- 239000013612 plasmid Substances 0.000 claims description 21
- 150000004665 fatty acids Chemical class 0.000 claims description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 19
- 239000000194 fatty acid Substances 0.000 claims description 19
- 229930195729 fatty acid Natural products 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 125000006853 reporter group Chemical group 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- RSRNHSYYBLEMOI-UHFFFAOYSA-M primuline Chemical compound [Na+].S1C2=C(S([O-])(=O)=O)C(C)=CC=C2N=C1C(C=C1S2)=CC=C1N=C2C1=CC=C(N)C=C1 RSRNHSYYBLEMOI-UHFFFAOYSA-M 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 description 91
- 108020003175 receptors Proteins 0.000 description 89
- 238000001228 spectrum Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 241000498849 Chlamydiales Species 0.000 description 14
- 241000606161 Chlamydia Species 0.000 description 13
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 13
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 241000606153 Chlamydia trachomatis Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- 229930186217 Glycolipid Natural products 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000001030 gas--liquid chromatography Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 241000589989 Helicobacter Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000003196 chaotropic effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000012539 chromatography resin Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 150000002298 globosides Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FOCMISOLVPZNSV-CANPYCKCSA-N N-[(E,2R,3S)-1-[5-[5-[3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](COC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3NC(C)=O)C(O)C2O)C(O)C1O)[C@@H](O)\C=C\CCCCCCCCCCCCC FOCMISOLVPZNSV-CANPYCKCSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001768 subcellular fraction Anatomy 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical group [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 208000015877 Duodenal disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000203736 Mobiluncus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101710110023 Putative adhesin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 208000018595 duodenum disease Diseases 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000010932 ethanolysis reaction Methods 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- VELGMVLNORPMAO-JTFNWEOFSA-N n-[(e)-1-[(3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxym Chemical compound O[C@@H]1[C@@H](O)C(OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-JTFNWEOFSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 206010030861 ophthalmia neonatorum Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 244000000033 sexually transmitted pathogen Species 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
- HFQKBOPMAOTAIR-TZSVBWBLSA-N α-d-galactosyl-(1->4)-β-d-galactosyl-(1->4)-β-d-glucosylceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(C)=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 HFQKBOPMAOTAIR-TZSVBWBLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates generally to receptors for microorganisms, complementary adhesins, adhesin genes, and methods of making and using these molecules.
- adhesins the structures on the microorganism that mediate binding of infectious agents to host cells are called adhesins, and the host cell structures recognized by microbial adhesins are called receptors. Therefore, the presence of receptors on host tissue is just as much a determinant of microbial infectivity as is the microorganisms' display of adhesins. Attempts to identify high avidity adhesins and their corresponding host cell receptors, however, have been unsuccessful.
- Chlamydia trachomatis An example of a pathogenic microorganism of concern to humans is Chlamydia trachomatis .
- This microorganism is an obligate intracellular bacterial parasite of eucaryotic cells and is now known to be the most common sexually transmitted pathogen in industrialized societies (Moulder in Microbiology of Chlamydia, ed. A. L. Barren, pages 3-19, CRC Press, Boca Raton, Florida, 1988; Schachter in Microbiology of Chlamydia. pages 153-166, 1988). In the United States, it has been estimated that more than four million people contract chlamydial-related diseases each year (Eisner & Monahan, Diagnostics and Clin. Testing .28.:26-28, 1990) .
- Salpingitis ectopic pregnancy, infertility, chronic pelvic pain, premature labor, neonatal conjunctivitis, infant pneumonia, endemic trachoma, urethritis, and epididymitis have all been directly or indirectly related to infection by the organism (Schachter 1988; Eisner & Monahan, 1990) .
- Another example of a pathogenic microorganism of concern to humans is ffeli ⁇ oJba ⁇ ter pylori .
- This microorganism is an infectious agent of the human stomach. Infection is associated with both primary, chronic-active gastritis, and peptic ulcer disease (Blaser, J. Infect. Pis. 161:621-623, 1990; Marshall, J. Infect. Pis. 153:650- 657, 1986; Marshall et al., Lancet jL:1437-1442, 1988).
- the present invention provides a variety of compositions and methods related to lipid receptors for microorganisms, the complementary microbial adhesins, and PNA seguences encoding adhesins.
- the present invention provides an isolated PNA molecule encoding an adhesin protein.
- the PNA molecule is cPNA.
- the PNA molecule is geno ic PNA.
- an isolated PNA molecule capable of specifically hybridizing with a PNA molecule encoding an adhesin protein.
- recombinant plasmids capable of expression in a host cell, the recombinant plasmid further comprising a PNA molecule encoding an adhesin protein
- Suitable promoters and/or polyadenylation signals are also disclosed.
- eukaryotic and prokaryotic cells transfected with recombinant plasmids comprising a PNA molecule encoding an adhesin protein, and methods for producing an adhesin protein using host cells transfected or transformed with a suitable PNA molecule are also disclosed.
- a method for producing an adhesin protein comprises: introducing into a host cell a recombinant plasmid capable of directing the expression of an adhesin protein in the host cell; growing the host cell in an appropriate medium; and isolating the protein product, encoded by the DNA sequence, produced by the host cell.
- the present invention discloses antibodies that specificaly bind to an adhesin protein. Preferred antibodies include monoclonal antibodies.
- an isolated receptor for microorganisms is provided.
- the receptor consists essentially of a plurality of phospholipids having the formula:
- R' is an alkyl group and R are alkyl, hydroxyalkyl or alkenyl groups of fatty acids.
- a pharmaceutical composition comprising a phospholipid described above in combination with a pharmaceutically acceptable carrier or diluent.
- the method consists essentially of the steps of: extracting the lipids of HeLa cells to yield a lipid extract; contacting the lipid extract with PEAE-agarose exchange resin under conditions sufficient to permit binding; washing with methanol the exchange resin to which the lipid extract has been contacted; eluting a fraction with methanol containing 10-20 mM NH4HCO 3 ; separating the fraction by silica gel preparative thin-layer chromatography; isolating a band positive for primuline and which binds a microorganism; washing the band with chloroform; and eluting the receptor from the band with methanol.
- Another aspect of the present invention provides methods useful for the screening for a microorganism which lacks an adhesin protein.
- the method comprises the steps of: contacting a receptor described above with an aliquot of a selected microorganism under conditions and for a time sufficient to allow binding to occur; and detecting the presence or absence of a bound microorganism, thereby determining the presence or absence of an adhesin protein in the microorganism.
- the present invention provides methods useful for the inhibition of microbial colonization.
- the method comprises administering to a warm-blooded animal an effective amount of a composition comprising a pharmaceutically acceptable carrier or diluent in combination with a phospholipid having the formula:
- X is — C R or — CH —CH R'
- Y is — C — R; and R' is an alkyl group and R are alkyl, hydroxyalkyl or alkenyl groups of fatty acids.
- the method comprises administering to a warm-blooded animal an effective amount of the composition described above additionally including GalNAc01 ⁇ 4Gal01-+4Glc-Ceramide.
- the method comprises administering to a warm-blooded animal an effective amount of the composition described above additionally including Gal01-»-3GalNAc01-»-4Gal01-»-4Glc-Ceramide.
- microbial adhesin proteins are disclosed.
- a microbial adhesin protein is characterized by having been prepared by the process consisting essentially of: contacting a receptor described above with a microorganism preparation, wherein the preparation contains an adhesin protein, under conditions and for a time sufficient to allow binding between the receptor and the adhesin protein; and isolating the adhesin protein.
- the present invention provides a vaccine comprising an adhesin protein described above in combination with a pharmaceutically acceptable carrier or diluent.
- Figure 1 shows the results of binding of C. trachomatis to lipids separated by thin-layer chromatography: (A) lipids visualized with orcinol reagent; (B) lipids visualized by overlaying with 125 l- labeled C. trachomatis followed by autoradiography for 48 h at -80°C; (C) lipids visualized by overlaying with 125 l- labeled C. trachomatis followed by autoradiography for 40 h at room temperature.
- CMH galactosylcera ide
- CPH lactosylceramide
- CTH trihexosylceramide
- GL4 globo
- FIG. 2 graphically illustrates the binding of C. trachomatis to immobilized lipids.
- 125 I-labeled C. trachomatis were incubated for 2 h at room temperature in microtiter wells coated with phosphatidylethanolamine extracted from HeLa 229 cells (-o-) , gangliotriaosylceramide (- ⁇ -) , gangliotetraosylceramide (- ⁇ -) , phosphatidylcholine (- D -) , lactosylceramide (- -) , and globoside (-•-) at the indicated concentrations.
- FIG. 3 graphically illustrates the binding of C. trachomatis to immobilized phospholipids.
- 125 I-labeled C. trachomatis were incubated for 2 h at room temperature in microtiter wells coated with various phosphatidylethanolamines from HeLa 229 cells (-o-) , soy bean (- - -) , yolk sac (- ⁇ -) , bovine brain (- • -) , bovine liver (- ⁇ -) , porcine liver (- A. -) , and E. coli (-4- -) , phosphatidylcholine (- C3 -) , and phosophatidylserine (- D -) at the indicated concentrations.
- Figure 4 shows the results of FAB mass spectrometry of: (A) Chlamydia receptor; (B) L- ⁇ - phosphatidylethanolamine from bovine brain (“bPE”) ; and (C) the receptor spectrum with the bPE spectrum subtracted. Samples were dissolved in triethanola ine and bombarded with xenon atoms with a kinetic energy of 8 keV and an accelerating voltage of 10 kV was used.
- Figure 5 shows the results of ⁇ -H-N R spectroscopy of bPE and Chlamydia receptor. Spectra were obtained in CP 3 OP at 27°C and chemical shifts are expressed relative to internal tetramethylsilane set to 0 ppm.
- Antibody - as used herein includes an intact molecule, a fragment thereof, or a functional equivalent thereof; and may be genetically engineered. Examples of antibody fragments include F(ab') 2 , Fab", Fab and Fv.
- Complementary PNA or cPNA - a PNA molecule or sequence which has been enzymatically synthesized from the sequences present in an mRNA template, or a clone of such a molecule.
- a plasmid generally contains at least one gene sequence to be expressed in the host cell, as well as sequences which facilitate such gene expression, including promoters and transcription initiation sites. It may be a linear or closed circular molecule.
- microorganisms bind specifically to host cell receptors.
- phospholipids are shown to be receptors for microorganisms and may be used to purify the corresponding adhesin proteins.
- microorganisms bind specifically to phospholipids isolated from human cells.
- Such microorganisms include Streptococci , Borrelia, Haemophilus, Pseudomonas, Neisseria, Helicobacter , Pasteurella, Campy lobacter , Erysipelothrix, Gardnerella, Propionibacterium, Treponema, Clostridium, Shigella , Bacteriodes, Fusobacterium, Chlamydia, Mycobacterium , Yersina , Coxiella, Vibrio, Pepto ⁇ treptococcus , Salmonella , and Mobiluncus .
- the host receptors for these microorganisms may be found on epithelial cells of the respiratory tract, gastrointestinal tract, or reproductive tract, or on blood or epidermal cells.
- Representative cultured cell lines include human oropharyngeal epithelial cells, human tracheal epithelial cells, human endometrial cells, human embryonic amnion cells, human gingival fibroblasts, HeLa cells, and McCoy cells.
- receptor Purification of the phospholipids responsible for binding (i.e., "receptor”) may be accomplished by a combination of extractions and chromatographic procedures. For example, briefly, cells (such as HeLa) are washed with phosphate buffered saline and extracted using chloroform/methanol/water. The extract is centrifuged, the pellet re-extracted, and the supernates combined ("lipid extract") . The lipid extract is applied to an anion exchange resin and, after a methanol wash, the receptor fraction is eluted with methanol containing 10- 20 mM NH 4 HCO 3 .
- the receptor fraction is further purified by preparative thin-layer chromatography, e.g., silica gel.
- the band containing the receptor is transferred to a glass column, washed with chloroform, and eluted with methanol. Purity may be assessed by analytical thin-layer chromatography.
- a purified receptor comprises the following phospholipid structure containing ethanolamine and several different fatty acids:
- Y is C R.
- R represents alkyl, hydroxyalkyl and alkenyl chains of fatty acids, and R' is an alkyl chain.
- Fatty acids are typically abbreviated by numerical designations.
- CH3(CH ) ⁇ 2 CH 2 CH COOH is 16:0 where the number to the left of the colon indicates the number of carbon atoms and the number to the right indicates the number of double bonds.
- the fatty acids identified in the purified receptor phospholipids from HeLa cells are 16:0, 18:1, 18:0, 20:4, and 18:90H + 18:10OH, and are present in relative proportions of about 16%, 17%, 47%, 1%, and 19%, respectively.
- This collection of phospholipids binds microorganisms specifically and with high avidity. Phospholipids of this type, but missing one or more of these particular fatty acids, also bind microorganisms.
- microorganisms also bind strongly to specific glycolipids.
- the GalNAc/Sl- ⁇ GalJl- ⁇ Glc sequences found in the .glycolipids asialo-GMl and asialo- GM2 appear to constitute a second receptor for microorganisms.
- Asialo-GMl is the abbreviation for Gal ⁇ l ⁇ 3GalNAc ⁇ l->4Gal01-"4Glc-Ceramide and asialo-GM2 has the same structure minus the terminal Gal.
- Ceramides are sphingolipid bases which are acylated on the amine with a fatty acid.
- the phospholipids of the present invention may be administered as a composition, which includes a pharmaceutically acceptable carrier or diluent, to a warm- blooded animal (such as a human) for inhibiting microbial colonization.
- a warm- blooded animal such as a human
- compositions may include one or more of the glycolipids described above.
- the precise optimal dose may vary, depending upon the particular phospholipid or glycolipid used. Generally, however, an effective amount will be from about 0.1 to about 10 mg per kg body weight.
- These phospholipids and glycolipids provide a means for preventing colonization by, for example, "fooling" a microorganism into binding to them (i.e., as an artificial receptor), rather than to a native receptor on a host cell.
- Pharmaceutically acceptable carriers and diluents include water, physiological saline, liposomes, alcohols, dimethyl sulfoxide (PMSO) and mixtures thereof.
- a composition may be administered by a variety of routes, including oral, parenteral and transdermal administration.
- the composition may be in pill, capsule or liquid form.
- physiological saline is a preferred diluent.
- PMSO is a preferred carrier.
- the phospholipids of the present invention may also be used, individually or collectively, to screen for microorganisms which lack an adhesin protein. Briefly, one or more of the receptor phospholipids are incubated with a sample of a microorganism such that, if an adhesin protein is present in the microorganism, the microorganism will bind to the phospholipid. Suitable microorganism samples include intact cells and cellular fractions which contain an adhesin, e.g., membrane preparations.
- the phospholipid may be attached to a solid support, such as a microtiter well or a chromatography resin (e.g., for column chromatography or thin-layer chromatography) . It may be desirable to remove substantially any unbound microorganism, e.g., by washing the solid support with a suitable buffer.
- a solid support such as a microtiter well or a chromatography resin (e.g., for column chromatography or thin-layer chromatography) . It may be desirable to remove substantially any unbound microorganism, e.g., by washing the solid support with a suitable buffer.
- a microorganism may be detected directly where a reporter group is attached to the microorganism sample.
- a microorganism may be detected indirectly (e.g., where a reporter group is attached to a molecule, such as an antibody, which binds to a microorganism) .
- Petection of immunocomplexes formed between a microorganism and antibodies that specifically bind to it may be accomplished by a variety of known techniques, such as radioimmunoassays (RIA) and enzyme-linked immunosorbent assays (ELISA).
- the antibodies may be labeled (i.e., have a reporter group attached) or may be unlabeled. Unlabeled antibodies can be used in combination with labeled molecules that are reactive with immunocomplexes (e.g., protein A) , or in combination with labeled antibodies (second antibodies) that are reactive with the antibody which binds to a microorganism.
- immunoassays are available, including those described in U.S. Patent Nos. 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,376,110; and 4,452,901.
- Suitable reporter groups for direct or indirect detection include radioisotopes, fluorophores, enzymes, lumines ⁇ ers, and dye particles. These and other labels are well known in the art and are described, for example, in the following U.S. patents: 3,766,162; 3,791,932; 3,817,837; 3,996,345; and 4,233,402.
- the receptor phospholipids described above may be used to isolate a microbial adhesin molecule. Briefly, a representative example of such an isolation begins with a microorganism preparation, such as a membrane extract, which contains an adhesin protein. Membrane extracts may be obtained using standard methodology.
- the extract is typically diluted 1:10 in a buffer containing bovine serum albumin. It may be desirable to additionally include a non-ionic detergent, such as octyl glucoside.
- the diluted extract is incubated with a receptor preparation, which has been immobilized onto a solid support, under conditions and for a time sufficient to allow binding to occur.
- Suitable solid supports include microtiter wells and chromatography resins, e.g., for column chromatography or thin-layer chromatography.
- the receptor may be immobilized onto a solid support by adsorption or covalent attachment. It will be evident to those skilled in the art that the receptor may be covalently attached in a variety of ways, including photoactivation and linker groups such as the homo- and hetero-functional reagents available from Pierce Chemical Co. (Rockford, 111.).
- the solid support, to which the adhesin molecules are bound via the receptor, is then washed to remove unbound material.
- the adhesin is then eluted with an elution buffer containing sodium dodecyl sulfate (SPS) or with a chaotropic agent, such as NaCI or KSCN.
- SPS sodium dodecyl sulfate
- a chaotropic agent such as NaCI or KSCN.
- an adhesin may be isolated by im unoaffinity using anti-adhesin antibodies.
- antibodies directed against an adhesin are bound, preferably covalently, to a solid support such as a ' chromatography resin.
- the subsequent steps are similar to those described above, where a receptor is the affinity ligand.
- the substantially pure adhesin may be analyzed by various analytical techniques, including SPS- polyacrylamide gel electrophoresis (SPS-PAGE) .
- SPS-PAGE SPS- polyacrylamide gel electrophoresis
- Isolated adhesin proteins appear to be a family of related proteins which range in molecular weight (as determined by SPS- PAGE) from about 40,000 to about 65,000, depending upon the particular microorganism.
- an adhesin protein isolated from the outer membrane of Haemophilus influenza has a molecular weight of about 47,000, a higher molecular weight adhesin protein appears present in Chlamydia and Helicobacter and a lower molecular weight adhesin protein appears present in Shigella flexneri and Streptomonas pneumonia. Since the microorganisms expressing related adhesin proteins are evolutionarily widely divergent, the common expression of these proteins is likely due to convergent adaptation.
- polyclonal or monoclonal antibodies which are capable of specifically binding (i.e., with a binding affinity of about 10 6 liters per mole) an adhesin protein may be produced.
- polyclonal antibodies may be produced by immunization of an animal with an adhesin protein and subsequent collection of its sera. Immunization is accomplished, for example, by systemic administration, such as by subcutaneous, intraplenic or intramuscular injection, into a rabbit, rat or mouse. It is generally preferred to follow the initial immunization with one or more booster immunizations prior to sera collection. Such methodology is well known and described in a number of references.
- MAbs may be generally produced by the method of Kohler and Milstein (Nature 256:495-497. 1975; Eur. J. Immunol. 6:511-519, 1976). Briefly, cells of lymph nodes and/or spleens of an animal immunized with an adhesin protein are fused with myeloma cells to form hybrid cell lines ("hybridomas" or "clones") . Each hybridoma secretes a single type of immunoglobulin specific for the adhesin protein, and, like the myeloma cells, has the potential for indefinite cell division.
- Suitable MAbs include those of murine or human origin, or chimeric antibodies such as those which combine portions of both human and murine antibodies (i.e., antigen binding region of murine antibody plus constant regions of human antibody) .
- Human and chimeric antibodies may be produced using methods well known by those skilled in the art.
- An alternative to the production of MAbs via hybridomas is the creation of MAb expression libraries using bacteriophage and bacteria (e . g. , Sastry et al., Proc. Natl. Acad. Sci. USA 86:5728-5732, 1989; Huse et al., Science 246:1275-1281, 1989) .
- An adhesin protein of the present invention may be used in a vaccine to prevent diseases associated with microbial infections. Interference with the interaction between receptor and adhesin is an effective basis for the prevention of the attachment of microorganisms to the receptors on host cells. Administration of an adhesin protein as a vaccine leads to an immune response in which antibodies which bind to the adhesin are produced. These antibodies inhibit binding of microorganisms to host cell receptors.
- adhesin protein which functions as an antigen
- other components in the vaccine such as a vehicle for antigen delivery and immunostimulatory substances designed to enhance the protein's immunogenicity.
- vehicles for antigen delivery include aluminum salts, water-in-oil emulsions, biodegradable oil vehicles, oil- in-water emulsions, biodegradable microcapsules , and liposomes.
- immunostimulatory substances include N-acetylmuramyl-L-alanine-P-isoglutamine (MPP) , lipopoly-saccharides (LPS) , and glucan.
- an adhesin protein may be prepared synthetically and that a portion of the protein (naturally-derived or synthetic) may be used.
- a peptide of the protein it may be desirable to couple the peptide hapten to a carrier substance, such as keyhole limpet hemocyanin.
- the present invention also discloses isolated
- PNA molecules including genomic PNA and cPNA, encoding an adhesin protein.
- the PNA of the present invention may be cloned into a microbial vector, such as a plasmid, or into a viral vector that may be harbored by a bacteriophage.
- PNA encoding an adhesin protein is identified by screening an appropriate genomic library (that contains microbial PNA) with a receptor or a monoclonal antibody to an adhesin.
- a genomic library comprises colonies of a single type of microorganism, generally bacteria like E. coli K12 (HB101) , into which pieces of foreign PNA have been inserted, generally by being incorporated into a plasmid, cosmid, or phage vector compatible with the microorganism.
- the library comprises clones of vectors into which different sequences of PNA have been operably and recoverably inserted, each of the vectors containing only one sequence of PNA.
- the vectors may be plasmids, cosmids, or phage genomes.
- segments of PNA will have been inserted into vectors in a manner that they will be expressed under appropriate conditions (i.e., in proper orientation and correct reading frame and with appropriate expression sequences, including an RNA polymerase binding sequence and a ribosomal binding sequence.)
- Suitable microorganisms are those that do not express the adhesin protein, such as E. coli HB101.
- the positive clones are isolated and the exogenous PNA sequence is recovered from one of the clones.
- the sequence is evaluated to determine if it encodes an adhesin protein.
- PNA may be sequenced according to the strategy of Sanger et al. (Proc. Natl. Acad. Sci. USA 74:5463-5467, 1977), typically through the aid of an automated PNA sequencer (e.g., available from Applied Biosystems, Foster City, Calif.).
- the genomic library comprises bacteria, such as E. coli infected by phage.
- the phage are bacteriophage lambda. Plaques produced by the phage-infected bateria are screened by adhesin protein receptors or monoclonal antibodies to identify those plaques containing bacteria that produce the adhesin protein. The screening involves contacting the plaques with the monoclonal antibody or the receptors to determine if binding has occurred, using standard techniques, e.g., by immunoassays. In this preferred embodiment, the positive clones are then isolated by purifying the positive plaques and inducing plasmid formation in the bacteria in the purified plaque with a helper phage according to standard techniques.
- colonies containing PNA that encodes an adhesin protein may be detected using PYNA Beads according to Olsvick et al.
- the previously described receptors may be crosslinked to tosylated PYNA beads M280, and these receptor-containing beads are then used to adsorb to colonies expressing an adhesin protein.
- Colonies not expressing an adhesin are removed by washing, and this process is repeated to obtain an appropriate enrichment. Putative adhesin-expressing colonies are then plated and confirmed by metabolically labeling each colony with 35 S-methionine and testing the ability of the colony to bind to a receptor as previously described.
- the PNA from several adhering clones may be compared to identify shared sequences, and these shared sequences may be further subcloned and characterized.
- the gene for a specific adhesin may be localized and identified by constructing non-adherent mutants of a specific pathogen. This may be accomplished by creating mutants using a transposable element such as TnPhoA (as described in Manoil et al.
- Alkaline phosphatase-positive mutants would indicate mutations within exported proteins. Since the adhesin for each microorganism is located on the outer membrane surface and therefore exported, this set of mutants contains a much reduced subset of mutants. The mutants are then screened for a loss in binding activity by procedures previously described.
- a PNA sequence for an adhesin protein can be modified by known techniques in view of the teachings disclosed herein. For example, different codons can be substituted that code for the same amino acid as the original codon. Alternatively, the substitute codons may code for a different amino acid that will not affect the binding capability and/or immunogenicity of the protein, or which may improve its binding capability and/or immunogenicity.
- oligonucleotide directed, site specific mutagenesis or other techniques to create single or multiple mutations such as replacements, insertions, deletions, and transpositions, as described in Botstein and Shortle, "Strategies and Applications of In Vitro Mutagenesis," Science 229:193-1210 (1985), can be employed. Since such modified PNA may be produced by the application of known techniques to the teachings contained herein, such PNA is within the scope of the present invention.
- the DNA sequence (or fragments thereof) of the invention can be used to obtain other PNA sequences that hybridize with it under conditions of moderate to high stringency, using general techniques known in the art. For example, stringent hybridization and washing condutions are described by Suggs et al. (in Pevelopmental Biology Using Purified Genes. Eds. P. Brown and C.F. Fox, p. 683, Academic Press, N.Y., 1981). Accordingly, the PNA of the present invention includes such PNA.
- the PNA of the present invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform a microorganism for the expression and production of an adhesin protein.
- recombinant plasmids capable of integration into a host cell comprise a promoter followed downstream by a PNA sequence encoding an adhesin protein. It may be desirable to include a polyadenylation signal downstream from the PNA sequence.
- One embodiment of a method for producing an adhesin protein comprises introducing into a host cell a PNA sequence encoding an adhesin protein. The host cells are grown in an appropriate medium and the protein product encoded by the PNA sequence produced by the host cell is isolated.
- DNA of the present invention may be joined to a wide veriety of other PNA sequences for introduction into an appropriate host cell.
- the companion PNA would depend upon the nature of the host cell, the manner of the introduction of the DNA into the host cell, and whether episomal maintenance or integration is desired.
- the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression.
- the PNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such controls are generally available in the expression vector.
- the vector is then introduced into the host through standard techniques. Not all of the hosts may be transformed by the vector. Therefore, it may be necessary to select for transformed host cells.
- One selection technique involves incorporating into the expression vector a PNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance.
- the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.
- Transformed host cells of the present invention express adhesin proteins. Such cells are cultured by known techniques, and the proteins are recovered by known techniques. Pepending upon the host and expression system used, the recombinant proteins of the present invention may be part of a fusion protein produced by the transformed host cells. Such proteins are recovered by known techniques, and the undesired part may be removed by known techniques. Alternatively, the fusion protein itself may be more immunogenic than the recombinant protein or polypeptide alone and, therefore, may itself be useful, e.g., in a vaccine.
- the adhesins can be further purified by the application of standard protein purification techniques, modified and applied in accordance with the teachings described herein.
- standard protein purification techniques include electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography (including ion exchange chromatography, affinity chromatography, immunoadsorbent affinity chromatography, reverse-phase high performance liquid chromatography, and gel permeation high performance liquid chromatography) , isoelectric focusing, and variations and combinations thereof.
- One or more of these techniques are employed sequentialy in a procedure designed to separate molecules according to their physical or chemical characteristics.
- the various fractions of materials obtained after each technique are tested for their ability to react with the adhesin receptors. Those fractions showing such activity are then subjected to the next technique in the sequential procedure, and the new fractions are tested again. The process is repeated until only one fraction reactive with the receptors remains and that fraction produces only a single band when subjected to polyacrylamide gel electrophoresis.
- the preferred techniques include those identified and described in U.S. Patent No. 4,446,122, issued May 1, 1984 to Chu et al., which is incorporated herein by reference.
- the adhesins are purified by receptor affinity chromatography or monoclonal antibody affinity chromatography.
- Adhesins of the present invention may be modified by protein modification techniques. Suitable techniques are well known and include those described by Means and Feeney (Chemical Modification of Proteins. Holden-Gay, 1971) . Such modifications include breaking the protein into fragments that contain at least one active site or the addition, substitution, or deletion of one or more amino acids to the protein or a fragment thereof. Preferably, such protein derivatives are immunologically cross-reactive with an adhesin protein, thus being capable of eliciting an antigenic response to a microorganism in an animal host. Such modifications may enhance the immunogenicity of the protein or have no effect on such activity. Modification techniques additionally include those disclosed in U.S. Patent No. 4,526,716, issued July 2, 1985 to Stevens.
- Adhesin proteins of the present invention may contain one or more amino acid sequences that are not necessary to its immunogenicity. For example, only the amino acid sequences of a particular epitope of the antigen may be necessary for immunogenic activity. Unwanted sequences can be removed by techniques well known in the art. For example, unwanted amino acid sequences can be removed via limited proteolytic digestion using enzymes such as trypsin, papain, or related proteolytic enzymes.
- polypeptides corresponding to various immunogenic epitopes and/or the receptor binding site of the protein may be chemically synthesized by methods well known in the art, given the teachings contained herein. These include the methods disclosed in U.S. Patent No. 4,290,944, issued September 22, 1981 to Goldenberg.
- Modified proteins may be prepared that are substantially homologous to an adhesin protein through the use of known techniques and routine experimentation in view of the teachings contained herein. Such a protein may be identified by the fact that it will bind to antibodies that were generated by use of an adhesin protein of the invention.
- EBs chlamydial elementary bodies
- Chlamydial organisms were radioiodinated as described for bacteria (Krivan et al., Arch. Biochem. Biophys. 260:493-496. 1988), with minor modifications. Briefly, 0.5 ml of the chlamydial suspension were reacted with 0.5 mCi of Na 125 I at an ice bath in a tube (10 x 75 mm) coated with 0.1 mg of Iodogen (Pierce Chemical Co., Rockford, 111.). After 4 to 5 min, the suspension was transferred to a centrifuge tube containing 5 ml of Tris- BSA buffer (0.05 M Tris hydrochloride [pH 7.8] containing 0.15 M NaCI and 1% bovine serum albumin).
- the tube was centrifuged at 30,000 x g for 30 min at 4°C and the supernatant fluid was removed. The pellet was resuspended in 6 ml of Tris-BSA buffer and the centrifugation was repeated. The supernatant fluid was removed and the pellet was resuspended in 5 ml of Tris-BSA buffer. The radioactivity of the suspension was adjusted to 2 x 10 6 cpm/ml for a chromatogram overlay assay and to 4 x 10 6 for a solid-phase binding assay with RPMI-BSA (RPMI 1640 medium [GIBCO Laboratories, Grand Island, N.Y.] containing 1% BSA) .
- RPMI-BSA RPMI 1640 medium [GIBCO Laboratories, Grand Island, N.Y.] containing 1% BSA
- the purified EBs were sonicated for 7 min in an ice bath using a microtip followed by centrifugation at 4°C for 30 min at 30,000 x g.
- the supernatant fluid was designated as sonic extract and its protein concentration was determined by BCA protein assay (Pierce Chemical Co.,
- bovine serum albumin as a standard.
- the sonic extract was radiolabeled as described for protein (Magnani et al., Meth. Enzvmol. 83:235-241.
- Tris-BSA Tris-BSA. After the mixture passed through the column, 1 ml of Tris-BSA was added to the top of the column and this was followed by adding more Tris-BSA. The first 1 ml was discarded and the next 5 ml was collected. The radioactivity of the sonic extract was adjusted to 2 x 10 6 cpm/ml for a chromatogram overlay assay and to 4 x 10 cpm/ml for a solid-phase binding assay with RPMI-BSA.
- the overlay assay was performed as described for bacteria (Krivan et al., Arch. Biochem. Biophys. 260:493- 496, 1988) . Briefly, lipids were chromatographed on aluminum-backed silica gel high-performance thin-layer plates (HPTLC; E. Merck AG, Darmstadt, Federal Republic of Germany), and developed with chloroform-methanol-0.25% aqueous KCl (5:4:1).
- HPTLC aluminum-backed silica gel high-performance thin-layer plates
- the plate was coated with polyisobutylmethacrylate (0.1% in hexane), air-dried, soaked for 1 h in Tris-BSA buffer, and overlayed for 2 h at room temperature with 125 I-labeled either chlamydial organisms or chlamydial subcellular fraction as described above.
- the plates were gently washed to remove unbound organisms, dried, and exposed for 40 h to XAR-5 X-ray film (Eastman Kodak Co., Rochester, N.Y.).
- the solid-phase binding assay was performed as described by Krivan et al.. Arch. Biochem. Biophvs. £60.:493-496, 1988. Briefly, serial dilutations of purified lipids in methanol (25 ⁇ l) containing cholesterol and phosphatidylcholine (0.1 ⁇ g each) were added to polyvinylchloride microdilution wells (Falcon 3919; Becton Pickinson and Co., Paramus, N.J.) and dried by evaporation.
- the wells were blocked with Tris-BSA for 1 h, rinsed with RPMI-BSA twice, and incubated with 25 ⁇ l of "I-labeled either chlamydial organisms or its subcellular fraction for 2 h at room temperature. After the wells were washed five times with PBS, the polyvinylchloride wells were cut with scissors and placed in counting tubes. Binding was quantified in a gamma counter.
- HeLa 229 were grown in TC-175 cm 2 flasks and harvested either by mild trypsinization or scrapping. Cells were washed three times in 0.0067 M phosphate buffered saline (PBS, pH 7.2). Total lipids of HeLa 229 cells were extracted by adding three volumes (to the wet weight of the cells) of deionized water, ten volumes of methanol and five volumes of chloroform. The mixture was ultrasonicated for 2 min and incubated overnight on a rocking bed at room temperature. The extract was centrifuged at 4°C for 5 min at 2,000 rpm. Supernatant fluid was saved and the pellet was resuspended in the same volumes of deionized water, methanol and chloroform. The suspension was ultrasonicated for 30 min and supernatant fluid was collected by centrifugation. The first and second supernatant fluids were combined in a round bottom flask and dried on a rotary evaporator.
- PBS phosphat
- the dried total lipid extract of HeLa 229 cells was solubilized in 1:1 methanol-chloroform (0.5 ml per 1 gram wet weight of the cells) . A portion of the total lipid was stored at -20°C for later analysis. The rest was dried under nitrogen and dissolved in the original volume of chloroform-methanol-water (30:60:8). The total lipids of HeLa 229 cells were applied to a PEAE-Sepharose CL-6B column (Pharmacia AB, Uppsala, Sweden) and allowed to bind for 20 min.
- Neutral lipids were eluted first with five gel volumes of methanol, then the fraction containing Chlamydia receptor ("receptor") was eluted with five gel volumes of methanol containing 10-20 mM NH 4 HCO 3 . Fractions containing receptor migrated between CMH and CPH as analyzed by HPTLC and were weakly orcinol positive. The phospholipid fractions were verified to contain the Chlamydia receptor by the ability to bind radiolabeled elementary bodies as analyzed by the chromatogram overlay assay described in Example 1. Other acidic lipids were eluted with five gel volumes of methanol containing 0.5 M NH4HCO 3 . Each lipid elution was dried on a rotary evaporator and redissolved in 1:1 methanol-chloroform.
- the fraction containing receptor was further purified by chromatographing on Silica Gel G-2000 microns thin-layer preparative plates (Anal. Tech, Newark, N.J.), developed with 5:4:1 chloroform-methanol-aqueous 0.25% KC1.
- the plates were sprayed with primuline and examined by a longwave U.V. light.
- the band containing receptor stains positive with primuline and binds Chlamydia in the chromatogram overlay assay as described in Example 1.
- the receptor band was scrapped out, minced and packed in a glass column. The column was washed with five gel volumes of chloroform, then receptor was eluted with ten gel volumes of methanol.
- the ⁇ -H-spectra of receptor ( Figure 5) showed characteristic signals for a lipid with CH 3 groups (0.85 ppm) and CH signals from aliphatic chains (1.3 ppm) . Substantial amounts of unsaturations in the fatty acid chains were evident from the bulk of signals around 5.4 ppm. A number of signals not deriving from fatty acids were seen in the area of 6-3 ppm. Two spin systems of equal intensities and with similar features both containing five signals were detected.
- the first system with ultiplet signal at 5.23 ppm was through cross-peaks in the COSY-spectrum connected to two AB-systems (CH -groups judged from their T- j _- relaxation) , one at 4.43 ppm and 4.17 ppm and the other at
- the other spin system showed a similar pattern, CH 2 at 5.17 ppm and a two-proton resonance at 3.98 ppm.
- the second AB-system showed a marked shift of the other AB-system to 3.0 and 3.95 ppm.
- This may indicate a change from an acylated to an alkylated CH -group.
- R and R' represent the hydrocarbon (or hydroxylated hydrocarbon) chains of fatty acids and plasmalogens, respectively.
- This interpretation was confirmed by recording a reference spectrum of L- ⁇ -phosphatidyl- ethanolamine obtained from bovine brain (bPE) and stated to contain 54% plasmalogen (i.e., a, ⁇ unsaturated alkyl chains) .
- plasmalogen i.e., a, ⁇ unsaturated alkyl chains
- sonic extract is radioiodinated according to Example I.B., and diluted 1:10 in 50 mM Tris- HC1, pH 7.8, containing 150 mM NaCI, and 1.0% bovine serum albumin (TBS-BSA) .
- TBS-BSA bovine serum albumin
- Other buffers may also be used and. when it is necessary to prevent the aggregation of proteins, a detergent, such as octyl glucoside, at a concentration of about 0.05% - 0.1% is also included during preparation of the sonic extract.
- the chlamydial sonic extract is added to microtiter wells which have been previously coated and fixed with human Chlamydia receptor.
- 0.8-1.0 micrograms of receptor is immobilized in wells as follows.
- the receptor glycolipids are serially diluted in 25 ⁇ l of methanol containing 100 ng each of the auxiliary lipids phosphatidylcholine and cholesterol in flat bottom wells of polyvinylchloride microtiter plates (Falcon 3912-III, Becton-Pickinson) . After the solutions are dried by evaporation, the wells are subsequently blocked for 2 hours with Tris-BSA and then rinsed with saline.
- the wells are washed 5 times with ice-cold saline. To elute 125 I-receptor-bound adhesin, the wells are finally incubated 30 minutes at 37°C with 0.05 ml of 10 mM Tris- HC1, pH 7.8, containing 0.1% sodium dodecyl sulfate (SDS) .
- SPS-PAGE SPS-polyacrylamide gel electrophoresis
- the adhesin is purified by using an affinity chromatography column where the Chlamydia receptor is immobilized onto an appropriate gel solid support, such as a hydrophobic gel support, e.g., octyl- agarose (Pharmacia, Piscataway, N.J.).
- a suitable affinity matrix is prepared by adsorbing the receptor to a hydrophobic gel in the presence of salts (e.g., as described for other lipids by Hirabayashi et al., J ⁇ . Biochem. 94. ⁇ 327-330, 1983).
- Photoactivatable hetero- bifunctional crosslinking agents may also be used to prepare lipid affinity matrices (e.g., Lingwood, J. Lipid Res. 5:1010-1012, 1984) . By the use of such agents, the receptor is covalently attached to the gel support.
- the sonic extract is loaded on the top of the gel and the column is washed to remove unbound material.
- the adhesin is then eluted with a chaotropic agent such as NaCI or KSCN, dialyzed and analyzed by SPS-PAGE and autoradiography.
- An unradiolabeled sonic extract may be processed by any of the above methods subsequent to, or parallel with, the radioiodinated extract in order to provide unlabeled, purified adhesin protein.
- H. pylori isolates LC3 and LC11 were cultured from gastric mucosal biopsy samples from children with antral gastritis. The organisms were stored in brucella broth with 10% glycerol and 10% fetal bovine serum at -70°C. ' Cultures are typically stored for a maximum of 6 months. Cultures were plated on Skirrow's medium and incubated at 37"C under reduced oxygen for 24 h. An inoculum from the plate was placed in 10 ml brucella broth supplemented with 10% fetal bovine calf serum in a disposable Erlenmeyer flask.
- a whole cell H. pylori polyvalent antibody was produced by intravenous injection of a 1500 g New Zealand white rabbit with formalized H. pylori strain LC3. Bacteria (10 4 ) in 0.5 ml phosphate-buffered saline were injected, followed 2 and 6 weeks later by injections of 10 8 organisms suspended in 1 ml phosphate-buffered saline. Antiserum was obtained by way of a venous catheter (with the rabbit under general anaesthesia) two weeks after the last injection. The presence of H. pylori antibody was shown by immunoblots of whole cell sonicates of six separate H. pylori isolates. The antibody reacted with the same proteins from each isolate.
- Lipid extracts 50 ⁇ g were separated by thin- layer chromatography on plastic-backed sheets (Polygram SIL-G, Brinkman Instruments, Ontario, Canada) in chloroform/methanol/water, 65:25:4 (by volume). The plates were blocked in 3% gelatin at 37 ⁇ C for 2 h. After washing, the plates were incubated at room temperature in a carbon dioxide/hydrogen atmosphere with freshly cultured H. pylori in growth medium (10 6 /ml) . After 2 h incubation, the plates were washed in 100 mmol/1 "tris" saline pH 7.6, incubated in a 1/600 dilution of rabbit H.
- Puri ication Lipids were extracted from outdated red blood cells, mucosal scrapings of pig stomach and of human stomach obtained at necropsy, and cultured HEp2 cells. The tissue was weighed, homogenized in a minimum volume of water, and extracted in 20 volumes of chloroform/methanol 2:1 (by volume) ; the extract was then partitioned against water. The lower-phase lipids were dried, dissolved in chloroform/methanol 98:2, and applied to a silicic acid column previously equilibrated in chloroform. The column was washed extensively in sequence with chloroform, acetone/methanol 9:1 (3:1 for red blood cell extracts), and methanol. The fractions were dried and weighed.
- the methanol fraction which contained the Helic ⁇ Jbacter-binding lipid, was concentrated, reapplied to a silicic acid column, and eluted with a linear polarity gradient of chloroform/methanol 10:1 to 2:1. Fractions were concentrated and tested for binding by the thin-layer chromatography overlay assay as described in Example 4. Those containing the receptor were pooled.
- H. pylori receptor Based on the results of the structural characterization of H. pylori receptor, it is a phosphatidylethanolamine-like molecule.
- native phosphatidylethanolammes are tested in the chromatogram overlay assay (described in Example 4.C. above)
- the PE from E. coli was the most effective receptor.
- PE from bovine brain, porcine liver, egg yolk, and soy bean were recognized to a lesser degree by H. pylori , while PE from bovine liver and dog brain showed no receptor activity.
- Example 5 CLONING OF ADHESIN PNA
- Balb/C mice are immunized with membranes from a microorganism possessing an adhesin, and their sera are tested for the development of antibody that inhibits the membranes from binding to receptor. Spleens from these mice are used to isolate splenocytes for fusion with SP2/0-AG14 (ATCC CRL 8287) mouse myeloma cells (according to Harlow et al., Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) . Positive fusion hybridoma cultures from separate fusions are screened for the production of antibody that reacted on ELISA with the membranes.
- SP2/0-AG14 ATCC CRL 8287
- the ELISA is performed as follows: Membranes containing 1 ⁇ g of protein are used to coat 96-well microtiter plates. The coated wells are washed with PBS (phosphate buffered saline, 10 mM sodium phosphate, pH 7.5, 167 mM sodium chloride), then incubated with serial 100 ⁇ l of hybridoma culture supernatant. The walls are washed, incubated with 100 ⁇ l of secondary goat anti-mouse antibody conjugated with horseradish peroxidase for 1 h, then bound antibody is detected colorimetrically (Biorad, Richmond, Calif.). Membrane-reactive hybridoma cultures are then tested for the ability to inhibit membrane binding.
- PBS phosphate buffered saline, 10 mM sodium phosphate, pH 7.5, 167 mM sodium chloride
- Hybridoma culture supematants are incubated with 4 x 10 6 cpm of 35 S-methionine labeled membranes for 1 h at room temperature. This mixture is then added to serial dilutions of receptor bound passively to 96-well microtiter plates and assayed for binding.
- the hybridoma cultures which produce suitable antibodies are cloned by limiting dilution to obtain stable cell lines according to Harlow et al.. Large amounts of antibody were produced in the ascites fluid of Balb/C mice, and the class of each antibody was determined according to Harlow et al.
- This ligation is then packaged into phage particles and used to tranfect the Escherichia coli host strain, XL-1 (according to Stratagene protocol) to obtain phage plaques which express proteins encoded by the foreign PNA. These plaques are used in an immunoblot screen with anti-adhesin antibody using a Stratagene Picoblue detection kit. Positive reacting plaques are purified and used to induce the production of a plasmid through the use of the helper phage R408 (according to Stratagene protocol) . These plasmids carry the insert PNA which encodes the adhesin protein. The location of the gene encoding the protein is determined by deletion analysis.
- Peletion analysis is performed by generation of subclones containing various restriction fragments in the vector pSK(-) (Stratagene) .
- the adhesin gene in clones testing positive for expression of adhesion protein is PNA sequenced according to the method of Sanger et al. (Proc. Natl. Acad. Sci. USA 74.:5463-5467, 1977).
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4502887A JPH06504670A (en) | 1990-12-21 | 1991-12-20 | Lipid receptors and corresponding adhesins for microorganisms, DNA sequences encoding adhesins, and methods for their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63237190A | 1990-12-21 | 1990-12-21 | |
US632,371 | 1990-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1992011367A2 true WO1992011367A2 (en) | 1992-07-09 |
WO1992011367A3 WO1992011367A3 (en) | 1992-10-15 |
Family
ID=24535261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/009810 WO1992011367A2 (en) | 1990-12-21 | 1991-12-20 | Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0563240A1 (en) |
JP (1) | JPH06504670A (en) |
CA (1) | CA2098733A1 (en) |
WO (1) | WO1992011367A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506139A (en) * | 1994-07-21 | 1996-04-09 | Connaught Laboratories Limited | Analog of haemophilus Hin47 with reduced protease activity |
US5656436A (en) * | 1994-07-21 | 1997-08-12 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
EP0842270A1 (en) * | 1995-06-07 | 1998-05-20 | Aktiebolaget Astra | Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics |
US5981503A (en) * | 1994-06-07 | 1999-11-09 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
US6020183A (en) * | 1994-07-21 | 2000-02-01 | Connaught Laboratries Limited | Analog of haemophilus Hin47 with reduced protease activity |
US6147057A (en) * | 1994-07-21 | 2000-11-14 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
WO2002095410A1 (en) * | 2001-05-18 | 2002-11-28 | Queensland University Of Technology | Adherent entities and uses therefor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985005037A1 (en) * | 1984-05-02 | 1985-11-21 | Syn-Tek Ab | Adhesin antigens, antibodies and dna fragment encoding the antigen, methods and means for diagnosis and immunization etc. |
EP0293079A2 (en) * | 1987-04-24 | 1988-11-30 | 368800 Alberta Ltd | Chlamydia vaccine |
-
1991
- 1991-12-20 JP JP4502887A patent/JPH06504670A/en active Pending
- 1991-12-20 CA CA002098733A patent/CA2098733A1/en not_active Abandoned
- 1991-12-20 EP EP19920902654 patent/EP0563240A1/en not_active Withdrawn
- 1991-12-20 WO PCT/US1991/009810 patent/WO1992011367A2/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985005037A1 (en) * | 1984-05-02 | 1985-11-21 | Syn-Tek Ab | Adhesin antigens, antibodies and dna fragment encoding the antigen, methods and means for diagnosis and immunization etc. |
EP0293079A2 (en) * | 1987-04-24 | 1988-11-30 | 368800 Alberta Ltd | Chlamydia vaccine |
Non-Patent Citations (3)
Title |
---|
Infection and Immunity, volume 55, no. 2, February 1987, Washington DC, US; G. Hinson et al.: "Adherence to human colonocytes of an Escherichia coli strain isolated from severe infantile enteritis: molecular and ultrastructural studies of a fibrillar adhesin", pages 393-402, see the whole article * |
Infection and Immunity, volume 58, no. 4, April 1990, Washington, DC, US Hua Sue et al.: "Chlamydia trachomatis host cell interactions: role of the chlamydial major outer membrane protein as an adhesin", pages 1017-1025, see the wole article * |
Journal of Bacteriology, volume 169, no. 11, November 1987, Baltimore, MD, US, R. Kaul et al.: "Cloning, expression and primary structure of a chlamydia trachomatis binding protein", pages 5152-5156, see the abstract and figure 3 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981503A (en) * | 1994-06-07 | 1999-11-09 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
US5962430A (en) * | 1994-07-21 | 1999-10-05 | Loosmore; Sheena M. | Analog of Haemophilus Hin47 with reduced protease activity |
US6025342A (en) * | 1994-07-21 | 2000-02-15 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
US6153580A (en) * | 1994-07-21 | 2000-11-28 | Loosmore; Sheena M. | Analog of haemophilus Hin47 with reduced protease activity |
US5869302A (en) * | 1994-07-21 | 1999-02-09 | Connaught Laboratories Limited | Analog of haemophilus hin47 with reduced protease activity |
US6147057A (en) * | 1994-07-21 | 2000-11-14 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
US5935573A (en) * | 1994-07-21 | 1999-08-10 | Connaught Laboratories Limited | Method of use of an analog of Haemophilus influenzae Hin47 with reduced protease activity |
US5665353A (en) * | 1994-07-21 | 1997-09-09 | Connaught Laboratories Limited | Composition containing an analog of haemophilus Hin47 with reduced protease activity |
US5656436A (en) * | 1994-07-21 | 1997-08-12 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
US5939297A (en) * | 1994-07-21 | 1999-08-17 | Connaught Laboratories Limited | Analog of haemophilus HIN47 with reduced protease activity |
US6020183A (en) * | 1994-07-21 | 2000-02-01 | Connaught Laboratries Limited | Analog of haemophilus Hin47 with reduced protease activity |
US5506139A (en) * | 1994-07-21 | 1996-04-09 | Connaught Laboratories Limited | Analog of haemophilus Hin47 with reduced protease activity |
US6114125A (en) * | 1994-07-21 | 2000-09-05 | Connaught Laboratories Limited | Analog of Haemophilus Hin47 with reduced protease activity |
EP0842270A4 (en) * | 1995-06-07 | 1999-02-24 | Astra Ab | Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics |
EP0842270A1 (en) * | 1995-06-07 | 1998-05-20 | Aktiebolaget Astra | Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics |
WO2002095410A1 (en) * | 2001-05-18 | 2002-11-28 | Queensland University Of Technology | Adherent entities and uses therefor |
Also Published As
Publication number | Publication date |
---|---|
WO1992011367A3 (en) | 1992-10-15 |
JPH06504670A (en) | 1994-06-02 |
EP0563240A1 (en) | 1993-10-06 |
CA2098733A1 (en) | 1992-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3771265B2 (en) | Moraxella high molecular weight major outer membrane protein | |
Holmgren et al. | Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine | |
US5102663A (en) | Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3 | |
Lingwood et al. | Receptor affinity purification of a lipid-binding adhesin from Helicobacter pylori | |
EP0546118B1 (en) | Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis | |
JP3797490B2 (en) | Isolated FrpB nucleic acid molecules and vaccines | |
EP0592470B1 (en) | Pseudomonas exoenzyme s peptide composition and methods for its production | |
Mattsby-Baltzer et al. | Lipid A in Helicobacter pylori | |
JP3066339B2 (en) | Influenza vaccine and diagnostic methods | |
US5164298A (en) | Verocytotoxin receptor assay | |
EP0563256B1 (en) | Use of host cell phospholipids for inhibiting bacterial colonization | |
EP0553113B1 (en) | Adhesion receptors for pathogenic or opportunistic microorganisms | |
WO1992011367A2 (en) | Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof | |
JP3330935B2 (en) | Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenza | |
RU2313536C2 (en) | Peptide concatemer inducing production of antibody against apolipoprotein b-100, vaccine for obesity treatment, method for preparing concatemer, polynucleotide, expressing vector | |
WO1993022423A1 (en) | Nutrient phospholipids for pathogenic bacteria | |
JP2002205999A (en) | Method for producing gm2-specific antibody | |
Kong et al. | Fucosylated glycosphingolipids of human myeloid cells | |
JP2000502244A (en) | Toxoplasma gondi saccharide complex | |
HUT52168A (en) | Process for preparing monoclonal antibody capable of recognizing specifically n-glycolyl-type gm under 2 and antibody-producing hybridome | |
PEDRON et al. | Preparation and binding specificity of a monoclonal antibody recognizing 3-deoxy-D-manno-2-octulosonic acid (Kdo) in lipopolysaccharides of Re chemotype | |
Hamid Elamin | Structural studies of enterotoxigenic E. coli type II heat-labile enterotoxins | |
WO1989001947A1 (en) | Protein derived from living body | |
Andre et al. | A Predominant Idiotype in the Gut Associated Lymphoid Tissue | |
JPH07509693A (en) | Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2098733 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992902654 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992902654 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992902654 Country of ref document: EP |